The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.
Lilly is dedicated to developing innovative new cancer medicines. Learn about those now available and in the oncology pipeline.
Eli Lilly drug pipeline fullReports on the drugs being developed by Eli Lilly & Co. that analysts predict will be successful in the market. Evista for osteoporosis; Gemzar for pancreatic cancer and non-small-cell lung cancer; ...
The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and potentially best-in-class, mutant-selective PI3Kαinhibitor currently in a Phase 1/2 clinical trial STX-478 could potentially address 30-40% of people with hormone-positive breast cancer, building on Lilly'...
"Lilly's optimism about the potential of our pipeline across therapeutic areas — cardiometabolic health, oncology, immunology and neuroscience — drives our unprecedented commitment to our domestic manufacturing build-out. Our confidence positions us to help reinvigorate domestic manufacturing, which will ...
the advancement of our pipeline as well as our ambitious manufacturing expansion agenda. All of this and the incredible work of our teams around the world give Lilly leadership confidence that we have a very bright future ahead and better opportunity than at any time in our company's history ...
Lilly is dedicated to developing innovative new cancer medicines. Learn about those now available and in the oncology pipeline.
The goodnewsabout donanemab, Eli Lilly’s Alzheimer’s drug, reached CEO Dave Ricks on July 2 as he was hiking in a remote part of Colorado. The pharmaceutical company had slogged for 35 years and spent $8 billion to develop an effective treatment for the terrible memory-robbing disease. ...
And I think there are some things in our pipeline and others that are getting me excited that maybe in five to seven years we could have good pain drugs that can alleviate the need for opioids. Mental health, there was a big wave of innovation Lilly led with drugs like Prozac or ...
OK. Thanks, Joe. In Q3, Lilly continued to make progress across the business. We delivered strong revenue growth, we advanced and expanded our pipeline, and we invested in new product launches, and continued expanding manufacturing network. ...